Mulholland Kristen, EVP and Chief HR Officer at Johnson & Johnson (JNJ), has demonstrated a clear net selling bias in their recent insider transactions, with $1.35 million in total sales outweighing $573,019 in purchases across 24 filings. The activity is concentrated entirely in JNJ shares, with no trades in other companies. A significant portion of the selling occurred on February 6, 2026, when Mulholland disposed of shares worth $800,367 (transaction code F) while acquiring $573,019 worth of shares (code M) on the same day—a notable same-day buy-sell pairing. Earlier transactions show a similar pattern, including a $251,153 sale on February 13, 2026, and multiple smaller dispositions in February 2025 ranging from $21,892 to $71,616. The most recent activity in February 2026 includes additional sales of $61,106 and $41,873, with no offsetting purchases during that period. While some transactions involve the acquisition of shares (likely through compensation-related mechanisms), the overall trend leans toward divestment, with Mulholland consistently reducing their position in JNJ over the observed period. The absence of any recent trades outside JNJ suggests a focused approach to managing their equity holdings in the healthcare giant.
AI-assisted summary